MELVILLE, N.Y., Sept. 20, 2017 -- North American Partners in Anesthesia (NAPA), one of the nation’s leading single-specialty anesthesia and perioperative management companies in the US, supports patient objections to insurer Harvard Pilgrim’s anesthesia coverage policy related to endoscopic procedures.
Harvard Pilgrim, a leading health services company that serves members in New Hampshire, throughout New England and beyond, provides coverage to more than 1.2 million members, according to its website.
In a Letter to the Editor entitled “Buyer Beware of Harvard Pilgrim” published in the New Hampshire Union Leader on August 20, 2017, the writer expressed outrage that Harvard Pilgrim now denies coverage for anesthesia during colonoscopies, offering “conscious sedation” instead. The full content of the letter is published here: http://www.unionleader.com/article/20170821/OPINION04/170829898/-1/opinion04
Unlike the vast majority of accredited healthcare providers, Harvard Pilgrim gastroenterologists are now required to perform endoscopic procedures on patients while simultaneously sedating them. This is not the accepted standard of care in the United States, and is underscored by the fact that GI fellows train to perform these procedures in concert with a qualified anesthesiologist.
As the patient points out in her letter, this policy is at odds with the coverage routinely offered by insurance providers nationwide, including Medicare and Medicaid. The writer questions Harvard Pilgrim’s motives, suggesting Harvard Pilgrim is focused on improving their bottom line with little regard for clinical quality, patient comfort and safety or accepted standards of care.
Under HP’s rules, patients are likely to get opioids such as fentanyl for sedation. NAPA shares the writer’s concern with the use of this drug, given the opioid crisis that exists in New Hampshire and throughout the U.S.
Anesthesia during colonoscopies is the accepted standard of care. Anesthesia provided by a qualified anesthesiologist has reduced patient anxiety, causing the number of screenings to increase, allowing providers, in turn, to catch cancers sooner. By contrast, with conscious sedation supported by insurer Harvard Pilgrim, discomfort is greater and patients often move during their procedure. This reduces the ability to see lesions, increases procedure time, escalates risk of trauma and prolongs patient recovery.
As the letter writer indicates, she cancelled her colonoscopy due to concerns with Harvard Pilgrim’s policy and her own comfort and safety. NAPA supports the writer’s suggestion that Harvard Pilgrim rethink its position on anesthesia during endoscopic procedures. This would ensure patients do not begin to avoid vital procedures and would bring Harvard Pilgrim’s policy in line with accepted standards of care.
About North American Partners in Anesthesia
As a clinician-led organization, North American Partners in Anesthesia (NAPA) is redefining healthcare, delivering unsurpassed excellence to its partners and patients every day. In three decades, NAPA has grown to become the nation’s leading single-specialty anesthesia and perioperative management company, serving more than one million patients annually in more than 200 healthcare facilities throughout the Northeast, Mid-Atlantic, Midwest and Southeast. For more information, visit NAPAanesthesia.com.
Media Contact
Barbara Cerrone
P: (516) 532-6715
E: [email protected]


DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 



